Colorado

Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment-1 Study (MISSION-1) will evaluate a six-month treatment of a medicine called tofacitinib to see if it can improve the health of individuals with Down syndrome.

This project will significantly increase the speed of Down syndrome research and the understanding of associated medical conditions such as leukemia and Alzheimer's disease.